|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 90 No. 12 (December 15), 1997:
pp. 4705-4709
RAPID COMMUNICATION
Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease
By
Jan Storek,
Ted Gooley,
Muriel Siadak,
William I. Bensinger,
David G. Maloney,
Thomas R. Chauncey,
Mary Flowers,
Keith M. Sullivan,
Robert P. Witherspoon,
Scott D. Rowley,
John A. Hansen,
Rainer Storb, and
Frederick R. Appelbaum
From the Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA.
 |
ABSTRACT |
Chronic graft-versus-host disease (GVHD) is likely caused by donor T lymphocytes. Because unmodified blood stem cell grafts contain one log more T lymphocytes than unmodified marrow grafts, we evaluated the incidence of chronic GVHD in previously reported 37 blood stem cell recipients and 37 computer-matched historical control marrow recipients (Bensinger et al, Blood 88:2794, 1996). All patients have been followed until death, relapse, or occurrence of chronic GVHD or for a minimum of 2 years. In a univariable proportional hazards regression model, the relative risk of developing clinical chronic GVHD (includes clinical limited and clinical extensive disease) by 2 years posttransplant among the peripheral blood stem cell recipients compared with the marrow recipients was 2.22 (95% confidence interval, 1.04 to 4.74; P = .039). For clinical extensive chronic GVHD, the relative risk was 2.37 (95% confidence interval, 1.07 to 5.29; P = .035). In multivariable analyses, considering also the covariables of patient age, patient cytomegalovirus serostatus, and donor cytomegalovirus serostatus, the relative risks of clinical chronic GVHD and clinical extensive chronic GVHD were also greater than 2 (P < .05). We conclude that the transplantation of unmanipulated filgrastim-mobilized blood stem cells may result in a relatively high incidence of chronic GVHD.
| |
INTRODUCTION |
ENTHUSIASM FOR transplantation of allogeneic cytokine-mobilized peripheral blood stem cells (PBSCs) has recently developed because several phase I/II studies suggest that transplanting PBSCs instead of marrow results in faster engraftment and possibly improved immune reconstitution.1-12 Donor T lymphocytes likely cause both acute and chronic graft-versus-host disease (GVHD).13 Despite the fact that PBSC grafts contain one log more T lymphocytes than marrow grafts,8,10,11 a higher incidence of acute GVHD after PBSC compared with marrow transplantation has not been observed in the phase I/II studies.1-9 However, it is possible that PBSC recipients have a higher incidence of chronic GVHD than marrow recipients, given the historical example of donor blood buffy coat infusions to patients with aplastic anemia: the recipients of buffy coat plus marrow had a significantly higher incidence of chronic GVHD than did the recipients of marrow, whereas the two groups did not differ markedly in the incidence of acute GVHD.14,15 Therefore, we evaluated whether the transplantion of unmodified PBSCs might be associated with a higher incidence of chronic GVHD than the transplantation of unmodified marrow.
| |
PATIENTS AND METHODS |
Patient characteristics have been described.8 Briefly, 37 consecutive adult patients who received granulocyte colony-stimulating factor (G-CSF )-mobilized PBSCs from an HLA-identical sibling as their first allotransplant for an advanced hematologic malignancy were included. The historical control group was composed of 37 HLA-identical sibling marrow transplant recipients who were computer-matched for the following variables: diagnosis, disease phase at transplant, patient age, and GVHD prophylaxis.
Diagnosis of clinical chronic GVHD and its classification into clinical limited or clinical extensive disease was performed by two chart reviewers (J.S. and M.S.) using published criteria.16 Concordant diagnosis and classification was made in 44 of the 46 patients who survived relapse-free beyond day 80. Discordant diagnosis or classification was made in the following 2 cases: (1) 1 marrow recipient treated with corticosteroids for acute skin, liver, and gut GVHD from the first month posttransplant until his death on day 81, who died of liver failure and disseminated aspergillosis; and (2) 1 PBSC recipient who at 6 months posttransplant developed rash (skin biopsy positive for GVHD) and primarily cholestatic liver test abnormalities (alkaline phosphatase 9 times the upper normal limit, biopsy not performed) that resolved with corticosteroids. In this report, both patients are considered to have had clinical extensive chronic GVHD.
Cox regression models were fit to compare the hazard of clinical chronic GVHD among patients who received PBSCs with the hazard among those who received marrow. A univariable model was fit in addition to a multivariable model. Each model contained the source of stem cells as an explanatory variable, and the multivariable model also considered pretransplant variables known to be associated with the development of chronic GVHD. Estimates of the incidence of GVHD were obtained using cumulative incidence estimates,17 in which death or relapse without chronic GVHD was considered a competing risk. Patients alive without relapse and without chronic GVHD at last follow-up were censored at this time. Prevalence estimates were also used to describe the incidence of active clinical extensive chronic GVHD among patients alive without relapse.18 All P values arising from regression models were obtained from the Wald test and are two-sided. No adjustments were made for multiple comparisons.
| |
RESULTS |
Among all 74 patients, 12 of 37 (32%) marrow recipients versus 20 of 37 (54%) PBSC recipients developed clinical chronic GVHD (Fig 1). Among 46 patients alive and relapse-free at day 80, 12 of 23 (52%) marrow recipients versus 20 of 23 (87%) PBSC recipients developed clinical chronic GVHD (Fig 2). Clinical extensive chronic GVHD occurred in 11 marrow and 18 PBSC recipients. All patients have been observed until death, relapse, or occurrence of chronic GVHD or for a minimum of 2 years.
View larger version (11K):
[in this window]
[in a new window]
| Fig 1.
The cumulative incidence of clinical chronic GVHD among all 37 bone marrow (BM) and all 37 PBSC recipients. The "×" tick marks denote patients who died or relapsed. The "|" tick marks denote patients who have not developed clinical chronic GVHD by the time of the last follow-up. Note that the horizontal axis scale between 0 and 2 years differs from that between 2 and 8 years posttransplant.
|
|
View larger version (11K):
[in this window]
[in a new window]
| Fig 2.
The cumulative incidence of clinical chronic GVHD among the 23 bone marrow (BM) and the 23 PBSC recipients surviving without relapse beyond day 80. The tick marks and the horizontal axis scale are as in Fig 1.
|
|
In the univariable proportional hazards regression model, PBSC recipients had 2.22 times higher hazard of developing clinical chronic GVHD by 2 years than did marrow recipients (95% confidence interval, 1.04 to 4.74; P = .039). In the multivariable models, the following potential predictors of chronic GVHD were considered as covariables: patient age, patient cytomegalovirus (CMV) serostatus pretransplant and donor CMV serostatus pretransplant.19-22 None of these covariables significantly altered the apparent association between the source of stem cells and the hazard of chronic GVHD that was seen in the univariable model. For clinical extensive chronic GVHD, the hazard of developing it by 2 years was 2.37 times higher among PBSC than marrow recipients in the univariable model (95% confidence interval, 1.07 to 5.29; P = .035). Again, none of the above potential predictors of chronic GVHD significantly altered the apparent association between the source of stem cells and the hazard of clinical extensive chronic GVHD in the multivariable models. Splenectomy, another potential predictor of chronic GVHD,22 was not included as a covariable because none of the patients surviving beyond day 80 had a history of splenectomy. Female donor parity, identified in previous work as possibly being associated with an increased hazard of chronic GVHD (Hansen, unpublished data),20 was not included as a covariable because of a small number of patients with parous female donors that would make a multivariable model unstable. Nevertheless, it is unlikely that the observed high incidence of chronic GVHD in PBSC recipients was due to a high proportion of PBSC recipients with parous female donors, because 3 of 23 PBSC versus 9 of 23 marrow recipients surviving without relapse beyond day 80 had parous female donors.
View larger version (11K):
[in this window]
[in a new window]
| Fig 3.
The prevalence of clinical extensive chronic GVHD among bone marrow (BM) and PBSC recipients surviving without relapse. Patients were considered to have ongoing clinical extensive chronic GVHD if they had been diagnosed with clinical extensive chronic GVHD and continued to receive immunosuppressive drugs. Note that the horizontal axis scale between 0 and 2 years differs from that between 2 and 8 years posttransplant.
|
|
De novo chronic GVHD (without preceding acute GVHD) appeared relatively common after PBSC grafting: Among the 12 marrow and the 20 PBSC recipients developing clinical chronic GVHD, 2 of 12 (17%) versus 9 of 20 (45%) patients had de novo disease.
The involvement of various organs with chronic GVHD is displayed in Table 1. There appears to be no major difference in the organs affected by post-PBSC and post-marrow transplant chronic GVHD.
The median Karnofsky performance score at 1 year after grafting was 90% (range, 80% to 100%) among the 10 marrow recipients and 85% (range, 60% to 100%) among the 14 PBSC recipients surviving without relapse by day 365. The difference was not statistically significant (P = .23, Mann-Whitney test).
Among the 37 PBSC recipients, 14 were alive at last contact. Their median length of follow up is 682 days (range, 506 to 1,128 days). Among the 37 marrow recipients, 11 were alive at last contact, and the median length of follow-up is 1,260 days (range, 819 to 2,605 days).
Of the 37 marrow recipients, 4 patients that have not developed relapse or clinical extensive chronic GVHD ("|" tick marks in Figs 1 and 2) were surviving at the time of the last follow-up (931, 1057, 1,488, and 2,705 days posttransplant). None of the 37 PBSC recipients survived without developing relapse or clinical extensive chronic GVHD (Fig 3). All marrow as well as PBSC recipients who had developed clinical extensive chronic GVHD were still on immunosuppressive drugs at the time of the last follow-up.
| |
DISCUSSION |
These data suggest that the incidence of chronic GVHD may be higher after PBSC than after marrow grafting. This was not detected at the time of our previous report8 most likely due to the short follow-up of the PBSC recipients (median, 285 days; range, 110 to 720 days) compared with that of the marrow recipients (median, 817 days; range, 295 to 2,224 days). Other groups have also reported a high incidence of chronic GVHD after PBSC transplantation.23-26 However, none of the previous reports presents a formal comparison of the PBSC recipients with similar marrow recipients.
It is not known why the incidence of acute GVHD does not whereas the incidence of chronic GVHD does appear higher after PBSC than marrrow transplantation.1-9,23,24 The relatively low incidence of acute GVHD in PBSC recipients despite the abundance of T cells in the PBSC grafts may be attributed to (1) G-CSF-induced preferential differentiation of T-helper cells into TH2 rather than TH1 cells, resulting in PBSC grafts with relatively few TH1 cells, that have been implicated in the pathogenesis of acute GVHD27-29; or (2) the large numbers of monocytes in PBSC grafts (up to 2-logs more than in marrow grafts) that suppress T cells.30-33 We speculate that the TH1  TH2 polarization may wane or that the immunosuppressive monocytes may die within months after grafting. The latter hypothesis would be consistent with our unpublished data and the published data of Ottinger et al10 showing that, whereas the counts of both monocytes and T cells are higher in PBSC than in marrow recipients during the first 2 months, thereafter the monocyte counts are similar, whereas the T-cell counts remain higher in the PBSC recipients compared with marrow recipients for at least 6 months after grafting.
Chronic GVHD and/or its treatment is associated with immune deficiency. Infections occur more frequently in long-term marrow transplant survivors with chronic GVHD than in those without chronic GVHD.34-36 Because PBSC grafts contain more than 1 log more CD4 T cells than marrow grafts,8,10,11 because this appears to result in higher CD4 T-cell counts in the PBSC compared with marrow recipients,10 and because CD4 T-cell counts appear to inversely correlate with infectious morbidity in long-term transplant survivors,37 infections could theoretically occur less frequently in PBSC recipients than in marrow recipients with chronic GVHD. This is in accord with the following observation. Among our 10 of 37 PBSC and 3 of 37 marrow recipients who survived until 1 year without relapse and who developed clinical chronic GVHD by 1 year posttransplant, the average number of infections (defined as in Sullivan et al38 ) between days 180 and 365 per patient was 0.4 in the PBSC and 1.3 in the marrow recipients.
Chronic GVHD has been associated with a low incidence of leukemic relapse.39,40 Therefore, PBSC transplantation could be associated with a low incidence of relapse.41 Indeed, Korbling et al25 reported a relapse rate of 18% among 100 PBSC recipients versus 40% among an unspecified number of marrow recipients by 2 years posttransplant. However, information on the comparability of the PBSC and the marrow recipients in, for example, disease type or disease status pretransplant was not reported. In our series, we have not observed a lower incidence of relapse among the PBSC recipients: 15 of 37 PBSC and 14 of 37 marrow recipients relapsed by 1 year posttransplant.
Currently, it is unclear whether the advantage of fast engraftment1-9 and the possible advantages of superior graft-versus-leukemia reaction25 and superior immune reconstitution10,11 outweigh the disadvantage of frequent chronic GVHD. Therefore, at present, allogeneic PBSC transplantation should not be routinely performed instead of marrow transplantation, except in the context of controlled trials. Whether the incidence of chronic GVHD is truly higher in PBSC than marrow recipients and whether this disadvantage is outweighed by the advantages of PBSCs will hopefully be resolved by ongoing controlled randomized trials.
| |
FOOTNOTES |
Submitted August 25, 1997;
accepted September 29, 1997.
Supported by National Institutes of Health Grants No. CA68496, CA18221, and CA18029.
Address reprint requests to Jan Storek, MD, FHCRC, M318, 1124 Columbia St, Seattle, WA 98104-2092.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
REFERENCES |
1.
Schmitz N,
Dreger P,
Suttorp M,
Rohwedder EB,
Haferlach T,
Loffler H,
Hunter A,
Russell NH:
Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor).
Blood
85:1666,
1995[Abstract/Free Full Text]
2.
Korbling M,
Przepiorka D,
Huh YO,
Engel H,
Vanbesien K,
Giralt S,
Andersson B,
Kleine HD,
Seong D,
Deisseroth AB,
Andreeff M,
Champlin R:
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma  Potential advantage of blood over marrow allografts.
Blood
85:1659,
1995[Abstract/Free Full Text]
3.
Bensinger WI,
Weaver CH,
Appelbaum FR,
Rowley S,
Demirer T,
Sanders J,
Storb R,
Buckner CD:
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor.
Blood
85:1655,
1995[Abstract/Free Full Text]
4. Brown RA, Adkins D, Goodnough M, Wehde D, Hendricks D, Ehlenbeck C, Laub L, DiPersio J: Allogeneic peripheral blood progenitor cell transplant does not appear to increase the risk of acute GVHD following HLA identical sibling transplant. Blood 86:393a, 1995 (abstr, suppl 1)
5.
Russell JA,
Brown C,
Bowen T,
Luider J,
Ruether JD,
Stewart D,
Chaudhry A,
Booth K,
Jorgerson K,
Coppes MJ,
Turener AR,
Larratt L,
Desai S,
Poon MC,
Klassen J:
Allogeneic blood cell transplants for haematological malignancy: Preliminary comparison of outcomes with bone marrow transplantation.
Bone Marrow Transplant
17:703,
1996[Medline]
[Order article via Infotrieve]
6.
Urbano-Ispizua A,
Solano C,
Brunet S,
Hernandez F,
Sanz G,
Alegre A,
Petit J,
Besalduch J,
Vivancos P,
Diaz MA,
Moraleda JM,
Carreras E,
Ojeda E,
DeLaRubia J,
Benet I,
Domingo-Albos A,
Garcia-Conde J,
Rozman C:
Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases.
Bone Marrow Transplant
18:35,
1996[Medline]
[Order article via Infotrieve]
7.
Bacigalupo A,
VanLint MT,
Valbonesi M,
Lercari G,
Carlier P,
Lamparelli T,
Gualandi F,
Occhini D,
Bregante S,
Valeriani A,
Piaggio G,
Pitto A,
Benvenuto P,
Figari O,
DeStefano G,
Caimo A,
Sessarego M:
Thiotepa cyclophosphamice followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood stem cells in adults with advanced leukemia.
Blood
88:353,
1996[Abstract/Free Full Text]
8.
Bensinger WI,
Clift R,
Martin P,
Appelbaum FR,
Demirer T,
Gooley T,
Lilleby K,
Rowley S,
Sanders J,
Storb R,
Buckner CD:
Allogeneic peripheral blood stem cell transplantation in patients with advanced hemotologic malignancies: A retrospective comparison with marrow transplantation.
Blood
88:2794,
1996[Abstract/Free Full Text]
9.
Przepiorka D,
Anderlini P,
Ippoliti C,
Khouri I,
Fietz T,
Thall P,
Mehra R,
Giralt S,
Gajewski J,
Deisseroth AB,
Cleary K,
Champlin R,
VanBesien K,
Andersson B:
Allogeneic blood stem cell transplantation in advanced hematologic cancers.
Bone Marrow Transplant
19:455,
1997[Medline]
[Order article via Infotrieve]
10.
Ottinger HD,
Beelen DW,
Scheulen B,
Schaeffer UW,
Grosse-Wilde H:
Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow.
Blood
88:2775,
1996[Abstract/Free Full Text]
11.
Storek J,
Witherspoon RP,
Maloney DG,
Chauncey TR,
Storb R:
Improved reconstitution of CD4 T cells and B cells but worsened reconstitution of serum IgG levels after allogeneic transplantation of blood stem cells instead of marrow (letter).
Blood
89:3891,
1997[Free Full Text]
12. Storek J, Witherspoon RP: Immunological reconstitution after hemopoietic stem cell transplantation, in Atkinson K (ed): Clinical Bone Marrow and Blood Stem Cell Transplantation: A Reference Textbook (ed 2). Cambridge, UK, Cambridge (in press)
13. Ferrara JLM, Deeg HJ, Burakoff SJ: Graft-vs.-Host Disease (ed 2). New York, NY, Marcel Dekker, 1997
14.
Storb R,
Doney KC,
Thomas ED,
Appelbaum F,
Buckner CD,
Clift RA,
Deeg HJ,
Goodell BW,
Hackman R,
Hansen JA,
Sanders J,
Sullivan K,
Weiden PL,
Witherspoon RP:
Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients.
Blood
59:236,
1982[Abstract/Free Full Text]
15.
Niederwieser D,
Pepe M,
Storb R,
Witherspoon R,
Longton G,
Sullivan K:
Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia.
Bone Marrow Transplant
4:151,
1989[Medline]
[Order article via Infotrieve]
16.
Shulman HM,
Sullivan KM,
Weiden PL,
McDonald GB,
Striker GE,
Sale GE,
Hackman R,
Tsoi MS,
Storb R,
Thomas ED:
Chronic graft-versus-host syndrome in man A long-term clinicopathologic study of 20 Seattle patients.
Am J Med
69:204,
1980[Medline]
[Order article via Infotrieve]
17.
Pepe MS,
Mori M:
Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?
Stat Med
12:737,
1993[Medline]
[Order article via Infotrieve]
18.
Pepe MS:
Inference for events with dependent risks in multiple endpoint studies.
J Am Stat Assoc
86:770,
1991
19. Sullivan KM: Graft-versus-host disease, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Boston, MA, Blackwell, 1994, p 339
20.
Atkinson K,
Horowitz MM,
Gale RP,
van Bekkum DW,
Gluckman E,
Good RA,
Jacobsen N,
Kolb HJ,
Rimm AA,
Ringden O,
Rozman C,
Sobocinski KA,
Zwaan FE,
Bortin MM:
Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation.
Blood
75:2459,
1990[Abstract/Free Full Text]
21.
Bostrom L,
Ringden O,
Sundberg B,
Ljungman P,
Linde A,
Nilsson B:
Pretransplant herpes virus serology and chronic GHVD.
Bone Marrow Transplant
4:457,
1989[Medline]
[Order article via Infotrieve]
22.
Bostrom L,
Ringden O,
Jacobsen N,
Zwaan F,
Nilsson B:
A European multicenter study of chronic GVHD.
Transplantation
49:1100,
1990[Medline]
[Order article via Infotrieve]
23.
Majolino I,
Saglio G,
Scime R,
Serra A,
Cavallaro AM,
Fiandaca T,
Vasta S,
Pampinella M,
Catania P,
Indovina A,
Marceno R,
Santoro A:
High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Bone Marrow Transplant
17:555,
1996[Medline]
[Order article via Infotrieve]
24. Urbano-Ispizua A, Garcia-Conde S, Brunet S, Hernandez F, Sanz G, Alegre A, Petit J, Bargay J, Vivancos P, Solano C, Ojeda E, Domingo A, Rozman C: High incidence of chronic GVHD after allogeneic peripheral blood progenitor cell transplantation from matched related donors. Blood 88:617a, 1996 (abstr, suppl 1)
25. Korbling M, Mirza N, Thall P, Przepiorka D, Anderlini P, Huh Y, Fisher H, Fahmy H, Champlin R: 100 HLA-identical allogeneic blood stem transplantations: The M.D. Anderson Cancer Cancer experience. Bone Marrow Transplant 19:S72, 1997 (abstr, suppl 1)
26.
Russell JA,
Desai S,
Herbut B,
Brown C,
Luider J,
Ruether JD,
Stewart D,
Chaudhry A,
Booth K,
Jorgenson K,
Coppes MJ,
Turner AR,
Larratt L,
Poon MC,
Klassen J:
Partially mismatched blood cell transplants for high-risk hematologic malignancy.
Bone Marrow Transplant
19:861,
1997[Medline]
[Order article via Infotrieve]
27.
Pan L,
Delmonte JJ,
Jalonen CK,
Ferrara JLM:
Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental GVHD.
Blood
86:4422,
1995[Abstract/Free Full Text]
28.
Pan L,
Bressler S,
Cooke KR,
Krenger W,
Karandikar M,
Ferrara JLM:
Long-term engraftment, GVHD, and immunologic reconstitution after experimental transplantation of allogeneic peripheral blood cells from G-CSF-treated donors.
Biol Blood Marrow Transplant
2:126,
1996[Medline]
[Order article via Infotrieve]
29.
Zeng D,
Dejbakhsh-Jones S,
Strober S:
Granulocyte colony-stimulation factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: Impact on blood progenitor cell transplantation.
Blood
90:453,
1997[Abstract/Free Full Text]
30.
Mielcarek M,
Martin PJ,
Torok-Storb B:
Suppression of alloantigen-induced T cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells.
Blood
89:1629,
1997[Abstract/Free Full Text]
31.
Ino K,
Singh RK,
Talmadge JE:
CD14+ suppressor cells in mobilized stem cell products.
J Leukoc Biol
61:583,
1997[Abstract]
32.
Kusnierz-Glaz CR,
Still BJ,
Amano M,
Zukor JD,
Negrin RS Blume KG,
Strober S:
Granulocyte colony-stimulating factor-induced comobilization of CD4-CD8- T cells and hematopoietic progenitor cells (CD34+) in the blood of normal donors.
Blood
89:2586,
1997[Abstract/Free Full Text]
33.
Nawa Y,
Teshima T,
Sunami K,
Hiramatsu Y,
Yano T,
Shinagawa K,
Omoto E,
Harada M:
Responses of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells to alloantigen stimulation (letter).
Blood
90:1716,
1997[Free Full Text]
34.
Atkinson K,
Farewell V,
Storb R,
Tsoi MS,
Sullivan KM,
Witherspoon RP,
Fefer A,
Clift R,
Goodell B,
Thomas ED:
Analysis of late infections after human bone marrow transplantation: Role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease.
Blood
60:714,
1982[Abstract/Free Full Text]
35. Sullivan KM, Mori M, Sanders J, Siadak M, Witherspoon RP, Anasetti C, Appelbaum FR, Bensinger W, Bowden R, Buckner CD: Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant 10:127, 1992 (suppl 1)
36.
Ochs L,
Shu XO,
Miller J,
Enright H,
Wagner J,
Filipovich A,
Miller W,
Weisdorf D:
Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients.
Blood
86:3979,
1995[Abstract/Free Full Text]
37.
Storek J,
Gooley T,
Witherspoon RP,
Sullivan KM,
Storb R:
Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts.
Am J Hematol
54:131,
1997[Medline]
[Order article via Infotrieve]
38.
Sullivan KM,
Storek J,
Kopecky KJ,
Jocom JJ,
Longton G,
Flowers M,
Siadak M,
Nims J,
Witherspoon RP,
Anasetti C,
Bowden R,
Applebaum FR,
Buckner CD,
Deeg HJ,
Hansen JA,
McDonald GB,
Sanders JE,
Storb R:
A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic GVHD following marrow transplantation: Clinical outcome and effect on subsequent immune recovery.
Biol Blood Marrow Transplant
2:44,
1996[Medline]
[Order article via Infotrieve]
39.
Sullivan KM,
Weiden PL,
Storb R,
Witherspoon RP,
Fefer A,
Fisher L,
Buckner CD,
Anasetti C,
Appelbaum FR,
Badger C:
Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia.
Blood
73:1720,
1989[Abstract/Free Full Text]
40.
Slavin S,
Akerstein A,
Naparstek E,
Or R,
Weiss L:
The graft-versus-leukemia phenomenon: Is GVL separable from GVHD?
Bone Marrow Transplant
6:155,
1990[Medline]
[Order article via Infotrieve]
41.
Glass B,
Uharek L,
Zeiss M,
Dreger P,
Loffler H,
Steinmann J,
Schmitz N:
Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus-leukemia effect.
Blood
90:1694,
1997[Abstract/Free Full Text]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Frangoul, E. R. Nemecek, D. Billheimer, M. A. Pulsipher, S. Khan, A. Woolfrey, B. Manes, C. Cole, M. C. Walters, M. Ayas, et al.
A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study
Blood,
December 15, 2007;
110(13):
4584 - 4587.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. C. Baumeister, K. Holig, M. Bornhauser, M. Meurer, E. P. Rieber, and K. Schakel
G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity
Blood,
October 15, 2007;
110(8):
3078 - 3081.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rutella, F. Zavala, S. Danese, H. Kared, and G. Leone
Granulocyte Colony-Stimulating Factor: A Novel Mediator of T Cell Tolerance
J. Immunol.,
December 1, 2005;
175(11):
7085 - 7091.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Banovic, K. P. A. MacDonald, E. S. Morris, V. Rowe, R. Kuns, A. Don, J. Kelly, S. Ledbetter, A. D. Clouston, and G. R. Hill
TGF-{beta} in allogeneic stem cell transplantation: friend or foe?
Blood,
September 15, 2005;
106(6):
2206 - 2214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. S. Tomas, F. R. Loberiza Jr, J. P. Klein, P. M. Layde, R. J. Lipchik, J. D. Rizzo, C. N. Bredeson, and M. M. Horowitz
Risk Factors for Bronchiolitis Obliterans in Allogeneic Hematopoietic Stem-Cell Transplantation for Leukemia
Chest,
July 1, 2005;
128(1):
153 - 161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Eapen, M. M. Horowitz, J. P. Klein, R. E. Champlin, F. R. Loberiza Jr, O. Ringden, and J. E. Wagner
Higher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry
J. Clin. Oncol.,
December 15, 2004;
22(24):
4872 - 4880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.M. Nagler and A. Nagler
The Molecular Basis of Salivary Gland Involvement in Graft-vs.-Host Disease
Journal of Dental Research,
February 1, 2004;
83(2):
98 - 103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Franzke, W. Piao, J. Lauber, P. Gatzlaff, C. Konecke, W. Hansen, A. Schmitt-Thomsen, B. Hertenstein, J. Buer, and A. Ganser
G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases
Blood,
July 15, 2003;
102(2):
734 - 739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Ringden, M. Labopin, A. Bacigalupo, W. Arcese, U.W. Schaefer, R. Willemze, H. Koc, D. Bunjes, E. Gluckman, V. Rocha, et al.
Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
December 15, 2002;
20(24):
4655 - 4664.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yamamoto, B. Wang, S. Fukuhara, S. Ikehara, and R. A. Good
Mixed peripheral blood stem cell transplantation for autoimmune disease in BXSB/MpJ mice
Blood,
August 13, 2002;
100(5):
1886 - 1893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Couban, D. R. Simpson, M. J. Barnett, C. Bredeson, L. Hubesch, K. Howson-Jan, T. B. Shore, I. R. Walker, P. Browett, H. A. Messner, et al.
A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies
Blood,
August 13, 2002;
100(5):
1525 - 1531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Lee, J. P. Klein, A. J. Barrett, O. Ringden, J. H. Antin, J.-Y. Cahn, M. H. Carabasi, R. P. Gale, S. Giralt, G. A. Hale, et al.
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse
Blood,
June 28, 2002;
100(2):
406 - 414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Guardiola, V. Runde, A. Bacigalupo, T. Ruutu, F. Locatelli, M. A. Boogaerts, A. Pagliuca, J. J. Cornelissen, H. C. Schouten, E. Carreras, et al.
Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes
Blood,
May 29, 2002;
99(12):
4370 - 4378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mehta, S. Singhal, C. Cutler, and J. H. Antin
Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell Transplantation: A Little Methotrexate Goes a Long Way
J. Clin. Oncol.,
January 15, 2002;
20(2):
603 - 606.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Morton, C. Hutchins, and S. Durrant
Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells
Blood,
December 1, 2001;
98(12):
3186 - 3191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Przepiorka, P. Anderlini, R. Saliba, K. Cleary, R. Mehra, I. Khouri, Y. O. Huh, S. Giralt, I. Braunschweig, K. van Besien, et al.
Chronic graft-versus-host disease after allogeneic blood stem cell transplantation
Blood,
September 15, 2001;
98(6):
1695 - 1700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Remberger, O. Ringden, I.-W. Blau, H. Ottinger, B. Kremens, M. G. Kiehl, J. Aschan, D. W. Beelen, N. Basara, G. Kumlien, et al.
No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors
Blood,
September 15, 2001;
98(6):
1739 - 1745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cutler, S. Giri, S. Jeyapalan, D. Paniagua, A. Viswanathan, and J. H. Antin
Acute and Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell and Bone Marrow Transplantation: A Meta-Analysis
J. Clin. Oncol.,
August 15, 2001;
19(16):
3685 - 3691.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Rowley, G. Donaldson, K. Lilleby, W. I. Bensinger, and F. R. Appelbaum
Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation
Blood,
May 1, 2001;
97(9):
2541 - 2548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Lapierre, N. Oubouzar, A. Auperin, D. Tramalloni, H. Tayebi, E. Robinet, M. Kuentz, D. Blaise, O. Hartmann, P. Herve, et al.
Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation
Blood,
May 1, 2001;
97(9):
2580 - 2586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. I. Bensinger, P. J. Martin, B. Storer, R. Clift, S. J. Forman, R. Negrin, A. Kashyap, M. E.D. Flowers, K. Lilleby, T. R. Chauncey, et al.
Transplantation of Bone Marrow as Compared with Peripheral-Blood Cells from HLA-Identical Relatives in Patients with Hematologic Cancers
N. Engl. J. Med.,
January 18, 2001;
344(3):
175 - 181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Matsubara, A. Makimoto, J. Takayama, T. Higa, T. Saito, Y. Kanda, R. Tanosaki, S. Mineishi, M. Ohira, and Y. Takaue
Possible Clinical Benefits of the Use of Peripheral Blood Stem Cells Over Bone Marrow in the Allogeneic Transplantation Setting for the Treatment of Childhood Leukemia
Jpn. J. Clin. Oncol.,
January 1, 2001;
31(1):
30 - 34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al.
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
J. Clin. Oncol.,
October 20, 2000;
18(20):
3558 - 3585.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Ratanatharathorn, E. Carson, C. Reynolds, L. J. Ayash, J. Levine, G. Yanik, S. M. Silver, J. L.M. Ferrara, and J. P. Uberti
Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host Disease
Ann Intern Med,
August 15, 2000;
133(4):
275 - 279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Champlin, N. Schmitz, M. M. Horowitz, B. Chapuis, R. Chopra, J. J. Cornelissen, R. P. Gale, J. M. Goldman, F. R. Loberiza Jr, B. Hertenstein, et al.
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
Blood,
June 15, 2000;
95(12):
3702 - 3709.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Arpinati, C. L. Green, S. Heimfeld, J. E. Heuser, and C. Anasetti
Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
Blood,
April 15, 2000;
95(8):
2484 - 2490.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Siena, R. Schiavo, P. Pedrazzoli, and C. Carlo-Stella
Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy
J. Clin. Oncol.,
March 13, 2000;
18(6):
1360 - 1377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Blaise, M. Kuentz, C. Fortanier, J. H. Bourhis, N. Milpied, L. Sutton, J.-P. Jouet, M. Attal, P. Bordigoni, J.-Y. Cahn, et al.
Randomized Trial of Bone Marrow Versus Lenograstim-Primed Blood Cell Allogeneic Transplantation in Patients With Early-Stage Leukemia: A Report From the Societe Francaise de Greffe de Moelle
J. Clin. Oncol.,
February 1, 2000;
18(3):
537 - 537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Appelbaum
Choosing the Source of Stem Cells for Allogeneic Transplantation: No Longer a Peripheral Issue
Blood,
July 15, 1999;
94(2):
381 - 383.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Ringden, M. Remberger, V. Runde, M. Bornhauser, I.W. Blau, N. Basara, K. Holig, D.W. Beelen, H. Hagglund, O. Basu, et al.
Peripheral Blood Stem Cell Transplantation From Unrelated Donors: A Comparison With Marrow Transplantation
Blood,
July 15, 1999;
94(2):
455 - 464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Engelhardt, H. Bertz, M. Afting, C. F. Waller, and J. Finke
High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34+ Immunoselection
J. Clin. Oncol.,
July 1, 1999;
17(7):
2160 - 2160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Pan, T. Teshima, G. R. Hill, D. Bungard, Y. S. Brinson, V. S. Reddy, K. R. Cooke, and J. L.M. Ferrara
Granulocyte Colony-Stimulating Factor-Mobilized Allogeneic Stem Cell Transplantation Maintains Graft-Versus-Leukemia Effects Through a Perforin-Dependent Pathway While Preventing Graft-Versus-Host Disease
Blood,
June 15, 1999;
93(12):
4071 - 4078.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Burt
Clinical Utility in Maximizing CD34+ Cell Count in Stem Cell Grafts
Oncologist,
June 1, 1999;
4(3):
265 - 268.
[Full Text]
|
|
|
|
|
|
|
M. N. Yenerel, D. Sargin, and Y. Tangun
High Risk of Chronic Graft-Versus-Host Disease in Unmanipulated Allogeneic Peripheral Blood Stem Cell Transplantation
Blood,
October 15, 1998;
92(8):
2973 - 2975.
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract